by Bronchiectasis is a condition in which the bronchial tubes of the lungs become abnormally widened due to damage to the tubes. It causes symptoms like chronic cough with mucus, shortness of breath, chest pain and recurrent lung infections. The drugs used for treatment of bronchiectasis are mainly aimed at reducing inflammation, clearing mucus and controlling infections. Some of the commonly prescribed drugs include antibiotics, bronchodilators and mucolytic agents. Constant innovation in drugs with fewer side effects and better efficacy is driving the growth of this market.
The global Bronchiectasis Drugs Market is estimated to be valued at US$ 303.8 Mn or Mn in 2023 and is expected to exhibit a CAGR of 10 % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the bronchiectasis drugs market is the emergence of novel targeted treatment options. Companies are developing monoclonal antibodies and gene therapies that focus on specific disease mechanisms like overexpression of certain proteins or genetic predispositions. For example, Insmed is developing amikacin liposome inhalation suspension, a novel formulation of the antibiotic amikacin for inhaled administration, to target chronic Pseudomonas lung infections in patients with bronchiectasis. Such emerging targeted treatments are more effective with fewer side effects and have potential to transform bronchiectasis management. This is expected to significantly boost the bronchiectasis drugs market during the forecast period.
Porter’s Analysis
Threat of new entrants: The threat of new entrants in the Global Bronchiectasis Drugs Market Size is low as extensive investment and availability of substitutes are required for launching new drugs in the market.
Bargaining power of buyers: The bargaining power of buyers in the bronchiectasis drugs market is moderate because of the presence of many branded and generic drugs available.
Bargaining power of suppliers: The bargaining power of suppliers in the bronchiectasis drugs market is low as raw materials are easily available.
Threat of new substitutes: The threat of new substitutes in the bronchiectasis drugs market is moderate as there are limited treatment options available for bronchiectasis.
Competitive rivalry: High as major players focus on expanding their product portfolio through mergers and acquisitions.
Key Takeaways
The global bronchiectasis drugs market is expected to witness high growth, exhibiting CAGR of 10% over the forecast period, due to increasing prevalence of respiratory infections.
Regionally, North America is expected to dominate the bronchiectasis drugs market during the forecast period. This is attributed to the presence of major market players and accessibility of advanced healthcare facilities in the region.
Key players operating in the bronchiectasis drugs market are GlaxoSmithKline plc, Novartis AG, Pfizer Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Sanofi S.A., Sunovion Pharmaceuticals Inc., Mylan N.V., Cipla Ltd., Grifols S.A., Insmed Incorporated, Arbor Pharmaceuticals LLC. Key players are focusing on expanding their product portfolio through mergers and acquisitions.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
